Arsenic compound sensitizes homologous recombination proficient ovarian cancer to PARP inhibitors
Abstract The poly(adenosine diphosphate-ribose) polymerase (PARP) inhibitors show survival benefits in ovarian cancer patients with BRCA1/2 mutation or homologous recombination (HR) deficiency, but only limited efficacy in HR-proficient ones. Another drug, arsenic trioxide (ATO) or arsenic drug (RIF...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Publishing Group
2021-09-01
|
| Series: | Cell Death Discovery |
| Online Access: | https://doi.org/10.1038/s41420-021-00638-2 |